<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041317</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia</dc:title>
<dc:description xml:lang="en">Introduction and objective. Hyperhomocysteinemia is associated to thrombosis and atherosclerosis. Vitamin B12 is among its main causes and may be due to a pernicious anemia. This study aimed to know the prevalence of this disease in patients who have venous thromboembolism and hyperhomocysteinemia. Patients and methods. A total of 80 consecutive patients (55 men and 25 women; age: mean [standard deviation] 63 [15] years) with pulmonary embolism and/or venous thrombosis and elevated values of homocysteine (&gt; 12 µmol/l) were studied. Results. Pernicious anemia was diagnosed (positive Schilling test, presence of anti-intrinsic factor antibodies and/or anti-parietal cells and fundal atrophic gastritis) in 5 patients (6.25% with range of age: 42-73 years. Only one of them had macrocytic anemia and there were no alterations in any of them in the thrombophilia study. The patients were treated with vitamin B12, administering it orally (1 mg/day) in 4 of them. The homocysteine and vitamin B12 values were normalized in every case at 6 months. Conclusions. Although the prevalence of pernicious anemia is not elevated in patients with venous thromboembolism and hyperhomocysteinemia, its existence must be ruled out to avoid other thrombotic and neurological complicationsIntroduction and objective. Hyperhomocysteinemia is associated to thrombosis and atherosclerosis. Vitamin B12 is among its main causes and may be due to a pernicious anemia. This study aimed to know the prevalence of this disease in patients who have venous thromboembolism and hyperhomocysteinemia. Patients and methods. A total of 80 consecutive patients (55 men and 25 women; age: mean [standard deviation] 63 [15] years) with pulmonary embolism and/or venous thrombosis and elevated values of homocysteine (&gt; 12 µmol/l) were studied. Results. Pernicious anemia was diagnosed (positive Schilling test, presence of anti-intrinsic factor antibodies and/or anti-parietal cells and fundal atrophic gastritis) in 5 patients (6.25% with range of age: 42-73 years. Only one of them had macrocytic anemia and there were no alterations in any of them in the thrombophilia study. The patients were treated with vitamin B12, administering it orally (1 mg/day) in 4 of them. The homocysteine and vitamin B12 values were normalized in every case at 6 months. Conclusions. Although the prevalence of pernicious anemia is not elevated in patients with venous thromboembolism and hyperhomocysteinemia, its existence must be ruled out to avoid other thrombotic and neurological complications</dc:description>
<dc:creator>Gómez González, P</dc:creator>
<dc:creator>Toledo Urgarte, T</dc:creator>
<dc:creator>Ribera Casado, C</dc:creator>
<dc:creator>Martín Mola, M</dc:creator>
<dc:creator>Fernández-Miranda, C</dc:creator>
<dc:creator>Yebra Yebra, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento y objetivo. La hiperhomocisteinemia se asocia a trombosis y aterosclerosis. Entre sus principales causas está la deficiencia de vitamina B12, que puede deberse a una anemia perniciosa. El objetivo del estudio ha sido conocer la prevalencia de esta enfermedad en los pacientes que presentan tromboembolia venosa e hiperhomocisteinemia. Pacientes y método. Se estudiaron consecutivamente 80 pacientes (55 varones y 25 mujeres; edad: media [desviación estándar]: 63 [15] años) con embolia pulmonar y/o trombosis venosa y valores elevados de homocisteína (&gt; 12 µmol/l). Resultados. En 5 pacientes (6,25%), con rango de edad: 42-73 años se diagnosticó una anemia perniciosa (prueba de Schilling positiva, presencia de anticuerpos antifactor intrínseco y/o anticélulas parietales y gastritis atrófica fúndica). Sólo uno de ellos tenía anemia macrocítica y en ninguno existían otras alteraciones en el estudio de trombofilia. Los pacientes se trataron con vitamina B12, administrándosela a 4 de ellos por vía oral (1 mg/día), y en todos los casos se normalizaron a los 6 meses los valores de homocisteína y de vitamina B12. Conclusiones. En los pacientes con tromboembolia venosa e hiperhomocisteinemia, aunque la prevalencia de anemia perniciosa no es elevada, es necesario descartar su existencia para evitar otras complicaciones trombóticas y neurológicas</dc:description>
<dc:source>Rev Clin Esp;205(10): 489-492, oct. 2005. tab</dc:source>
<dc:identifier>ibc-041317</dc:identifier>
<dc:title xml:lang="es">Tromboembolia venosa e hiperhomocisteinemia como primera manifestación de una anemia perniciosa</dc:title>
<dc:subject>^d14308^s22032</dc:subject>
<dc:subject>^d14308^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d767^s22016</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d33775^s22027</dc:subject>
<dc:subject>^d33775^s22016</dc:subject>
<dc:subject>^d16591^s22012</dc:subject>
<dc:subject>^d15204^s22000</dc:subject>
<dc:subject>^d767^s22032</dc:subject>
<dc:type>article</dc:type>
<dc:date>200510</dc:date>
</metadata>
</record>
</ibecs-document>
